Abstract
Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenemia of ovarian theca cell origin. Here we report the significant association of 15 single nucleotide polymorphisms (SNPs), identified by whole exome sequencing (WES). DNA was isolated from well-characterized theca cell preparations from women of European ancestry with PCOS (N=9) and elevated androgen production in vitro and from normal ovulatory women (N=7). Of the SNPs, 10 are located within 150 kb on chromosome 12q13.2. This region contains three plausible PCOS candidate genes (ERBB3/PA2G4/RAB5B), two of which (ERBB3 and RAB5B) have been identified in GWAS of PCOS. None of the SNPs individually had a significant association with PCOS or in vivo androgen levels when evaluated in an independent cohort (n=318) of families with one or more daughters with PCOS, but a haplotype consisting of the minor alleles of three of the SNPS (rs773121, rs773123 and rs812826) was found preferentially in women with PCOS and elevated androgen levels (p=0.0583). Moreover, the three minor alleles in this haplotype were significantly associated with anti-Mullerian Hormone (AMH) levels, a marker of follicular reserve and follicular maturation. Two of the three SNP minor alleles are predicted to have significant functional consequences (rs773123 a missense SNP in ERBB3, and rs812826, a SNP in the PA2G4 promoter). Notably, PA2G4 encodes a protein that interacts with the ERBB3 cytoplasmic domain, which is also the domain where the missense variant resides. These findings provide support for the contribution and probable functional significance of loci on chromosome 12q13.2 to the pathophysiology underlying PCOS.
Author Summary Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of women of reproductive age. We identified 15 single nucleotide polymorphisms (SNPs) associated with androgen production in theca cells from normal ovulatory women and women with PCOS. Of these SNPs, 10 are within a 150 kbp region of chromosome 12 including 9 that form a haplotype. This region contains three PCOS candidate genes (ERBB3/PA2G4/RAB5B). These SNPs were further examined in an independent cohort of families with one or more daughters with PCOS. A haplotype consisting of the minor alleles of three of the SNPS was found preferentially in women with PCOS. Furthermore, the three minor alleles in this haplotype were significantly associated with anti-Mullerian Hormone (AMH) levels, a marker of follicular reserve and maturation. Two SNPs in the chromosome 12 haplotype were likely to have functional consequences based on genomic context, suggesting that they affect ERBB3 and PA2G4 interactions or PA2G4 expression.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded in part by the National Institutes of Health grants R01HD083323 (to J.M.M and J.F.S.), R01HD100812 (to A.D.), and R01HD108744 (to A.D.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Boards of Northwestern University Feinberg School of Medicine, Penn State Health Milton S. Hershey Medical Center, and Brigham and Women's Hospital. Written informed consent was obtained from all subjects prior to the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
rharris1{at}bcm.edu, archer.43{at}osu.edu, mark.goodarzi{at}cshs.org, tpyork{at}vcu.edu, jr13{at}bcm.edu, andrea.dunaif{at}mssm.edu, jxm63{at}psu.edu, jerome.strauss{at}pennmedicine.upenn.edu
Data Availability
All data produced in the present work are contained in the manuscript
